R&D
A One-Time CRISPR Treatment Cut “Bad” Cholesterol in Half — and It Held for a Year
CRISPR Therapeutics’ CTX310 switches off the ANGPTL3 gene in the liver. One-year follow-up in a small first-in-human trial shows LDL and triglycerides stayed down with no serious treatment-related side effects.